Valproate (Depakote)

Valproate — Depakote — is the workhorse mood stabilizer for acute mania. It works faster than lithium, particularly excels in mixed episodes and rapid cycling, and can be loaded aggressively when the situation demands. For severe inpatient mania, valproate is often where treatment begins.

The mechanism is multi-target. Valproate enhances GABAergic transmission, blocks voltage-gated sodium channels, inhibits histone deacetylase (HDAC), and affects multiple downstream gene expression pathways. The antimanic mechanism is not cleanly attributable to any one of these, but the clinical effect — rapid mood stabilization in mania — is well established.

Onset is faster than lithium. A patient can be loaded with valproate over a few days, with measurable effect within the first week. Target serum levels are 50 to 125 micrograms per milliliter for mood stabilization. For acute mania, levels at the higher end of the range are often required.

Valproate is broad-spectrum across the bipolar phases. It excels in acute mania, including mixed states (where lithium underperforms) and rapid cycling (where lithium also underperforms). It has efficacy in maintenance. It is less effective specifically for bipolar depression than other agents like quetiapine or lamotrigine, so for the patient whose pole is predominantly depressive, valproate is not first choice.

The teratogenicity is the central problem with valproate, and it shapes prescribing for half the patient population. Valproate is among the most teratogenic psychiatric medications. First-trimester exposure increases neural tube defects roughly 4-5 fold over baseline. Exposure throughout pregnancy has been associated with cognitive impairment in offspring — measurable IQ reductions in exposed children — and with a constellation called fetal valproate syndrome. FDA pregnancy category X for the bipolar indication. The standard of care is to avoid valproate in women of childbearing potential when alternatives exist, and to discuss contraception and pregnancy planning explicitly with any woman who is prescribed it.

Other monitoring concerns: hepatotoxicity, especially in young children, requiring baseline and ongoing LFTs. Thrombocytopenia, requiring CBC. Pancreatitis, watching for severe abdominal pain. Hyperammonemia, which can present as mental status changes — check ammonia level in any patient on valproate with new confusion or somnolence. Polycystic ovary syndrome features in some long-term female patients. Weight gain.

Dosing: start 250 milligrams BID or TID and titrate. For acute mania, loading doses of 20-30 milligrams per kilogram are sometimes used to reach therapeutic levels quickly. Target levels guide dosing more than fixed total doses. Most patients end up between 750 and 2500 milligrams daily.

For the male patient or the woman past childbearing potential with bipolar mania, valproate is a strong first-line option. For the woman of childbearing potential, the conversation gets more complicated — and lithium, lamotrigine, or specific atypical antipsychotics are usually preferred.